Morgan Stanley Verve Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 913,191 shares of VERV stock, worth $4.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

913,191

Previous 623,730 46.41%

Holding current value

$4.16 Million

Previous $3.04 Million 45.22%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.4 - $7.86 $1.27 Million - $2.28 Million	289,461 Added 46.41%	913,191 $4.42 Million
Q2 2024 Oct 17, 2024	SELL	$4.76 - $12.79 $1.25 Million - $3.35 Million	-261,836 Reduced 29.57%	623,730 $3.04 Million
Q2 2024 Aug 14, 2024	SELL	$4.76 - $12.79 $1.25 Million - $3.35 Million	-261,836 Reduced 29.57%	623,730 $3.04 Million
Q1 2024 Oct 17, 2024	BUY	$10.81 - $17.96 $2.83 Million - $4.7 Million	261,836 Added 41.98%	885,566 $11.8 Million
Q1 2024 Aug 16, 2024	BUY	$10.81 - $17.96 $5.82 Million - $9.67 Million	538,665 Added 155.28%	885,566 $11.8 Million
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $5.82 Million - $9.67 Million	538,665 Added 155.28%	885,566 $11.8 Million
Q4 2023 Aug 16, 2024	SELL	$8.84 - $18.7 $2.45 Million - $5.18 Million	-276,829 Reduced 44.38%	346,901 $4.84 Million
Q4 2023 Feb 13, 2024	BUY	$8.84 - $18.7 $447,949 - $947,585	50,673 Added 17.11%	346,901 $4.84 Million
Q3 2023 Nov 15, 2023	SELL	$11.42 - $20.82 $523,332 - $954,097	-45,826 Reduced 13.4%	296,228 $3.93 Million
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $1.35 Million - $2.01 Million	101,233 Added 42.04%	342,054 $6.41 Million
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $2.06 Million - $3.45 Million	143,878 Added 148.42%	240,821 $3.47 Million
Q4 2022 Feb 14, 2023	SELL	$17.85 - $40.7 $631,586 - $1.44 Million	-35,383 Reduced 26.74%	96,943 $1.88 Million
Q3 2022 Nov 14, 2022	SELL	$15.63 - $41.49 $1.02 Million - $2.71 Million	-65,220 Reduced 33.02%	132,326 $4.55 Million
Q2 2022 Oct 27, 2022	SELL	$11.14 - $23.17 $214,177 - $445,466	-19,226 Reduced 8.87%	197,546 $3.02 Million
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $214,177 - $445,466	-19,226 Reduced 8.87%	197,546 $3.02 Million
Q1 2022 Oct 27, 2022	BUY	$20.92 - $39.36 $402,207 - $756,735	19,226 Added 9.73%	216,772 $4.95 Million
Q1 2022 May 13, 2022	BUY	$20.92 - $39.36 $4.18 Million - $7.86 Million	199,616 Added 1163.53%	216,772 $4.95 Million
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $359,867 - $617,656	11,267 Added 191.32%	17,156 $632,000
Q3 2021 Nov 15, 2021	BUY	$46.0 - $73.99 $270,894 - $435,727	5,889 New	5,889 $276,000

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $273M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account